Equities Analysts Set Expectations for CRBP FY2029 Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Equities research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Corbus Pharmaceuticals in a research report issued to clients and investors on Monday, February 10th. HC Wainwright analyst A. Maldonado forecasts that the biopharmaceutical company will post earnings per share of ($3.56) for the year. HC Wainwright has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share.

Other research analysts have also issued research reports about the stock. Wedbush restated an “outperform” rating and set a $51.00 price target on shares of Corbus Pharmaceuticals in a research note on Monday, November 4th. StockNews.com raised Corbus Pharmaceuticals to a “sell” rating in a research report on Monday, January 13th. Finally, Piper Sandler began coverage on Corbus Pharmaceuticals in a research report on Monday, December 2nd. They set an “overweight” rating and a $35.00 price target for the company. One analyst has rated the stock with a sell rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $61.38.

Corbus Pharmaceuticals Stock Down 10.2 %

Shares of Corbus Pharmaceuticals stock opened at $8.78 on Wednesday. The company has a 50 day moving average price of $12.49 and a 200 day moving average price of $26.68. Corbus Pharmaceuticals has a 52 week low of $8.74 and a 52 week high of $61.90.

Institutional Investors Weigh In On Corbus Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Street Corp lifted its holdings in shares of Corbus Pharmaceuticals by 34.6% in the 3rd quarter. State Street Corp now owns 595,576 shares of the biopharmaceutical company’s stock valued at $12,287,000 after buying an additional 153,243 shares during the period. Geode Capital Management LLC lifted its holdings in Corbus Pharmaceuticals by 8.1% in the third quarter. Geode Capital Management LLC now owns 249,759 shares of the biopharmaceutical company’s stock valued at $5,154,000 after acquiring an additional 18,702 shares during the period. HealthInvest Partners AB boosted its position in Corbus Pharmaceuticals by 41.3% in the 4th quarter. HealthInvest Partners AB now owns 98,304 shares of the biopharmaceutical company’s stock worth $1,188,000 after purchasing an additional 28,731 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Corbus Pharmaceuticals by 4.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 97,882 shares of the biopharmaceutical company’s stock worth $1,155,000 after purchasing an additional 4,239 shares during the period. Finally, HighVista Strategies LLC increased its holdings in shares of Corbus Pharmaceuticals by 94.1% during the 3rd quarter. HighVista Strategies LLC now owns 75,292 shares of the biopharmaceutical company’s stock valued at $1,553,000 after purchasing an additional 36,499 shares in the last quarter. 64.64% of the stock is owned by institutional investors and hedge funds.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.